or Try an Advanced Search...

    Technical Analysis for AMLX - Amylyx Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    B 5.64 4.44% 0.24
    AMLX closed up 4.44 percent on Friday, November 1, 2024, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Very Strong Up Up Up
    Historical AMLX trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    Up 3 Days in a Row Strength 0.00%
    NR7 Range Contraction 4.44%
    Wide Bands Range Expansion 4.44%
    Overbought Stochastic Strength 4.44%
    Wide Bands Range Expansion 7.02%
    Overbought Stochastic Strength 7.02%
    200 DMA Support Bullish 11.24%
    Slingshot Bullish Bullish Swing Setup 11.24%
    Older End-of-Day Signals for AMLX ...

       Recent Intraday Alerts

    Alert Time
    Up 5% about 23 hours ago
    60 Minute Opening Range Breakout about 23 hours ago
    Up 3% about 23 hours ago
    Rose Above Previous Day's High about 24 hours ago
    Up 2% about 24 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    AMLX Chart by TradingView
    Basic chart:

    Profile

    Amylyx Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company is developing AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid for the treatment of ALS and other neurodegenerative diseases. It is also developing products for Wolfram syndrome and Alzheimer's diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Life Sciences Pharmaceutical Alzheimer's Disease Neurodegenerative Diseases Amyotrophic Lateral Sclerosis Nervous System Neurodegenerative Disease Apoptosis

    Is AMLX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 26 Perceptive Advisors LLC's Strategic Acquisition in Amylyx Pharmaceuticals Inc
    Oct 23 Amylyx upgraded to buy by BofA on hypoglycemia drug potential
    Oct 21 October 2024's US Penny Stocks Poised For Growth
    Oct 19 Amylyx Pharmaceuticals (AMLX): Leading Nano Cap in Neurodegenerative Disease Treatments
    Oct 18 Amylyx’s AMX0035 shows promise in Phase II Wolfram syndrome trial
    Oct 18 Why Amylyx Pharmaceuticals Stock Was So Healthy This Week
    Oct 18 PTC rebuffed again by EMA; Novartis licenses China-based biotech’s cancer drug
    Oct 17 Amylyx Pharmaceuticals reports results from pancreatic disease treatment trial
    Oct 17 Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome
    Oct 15 Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024
    See more AMLX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 19.9488
    52 Week Low 1.575
    Average Volume 1,342,495
    200-Day Moving Average 4.86
    50-Day Moving Average 3.36
    20-Day Moving Average 4.41
    10-Day Moving Average 5.11
    Average True Range 0.43
    RSI (14) 77.58
    ADX 56.52
    +DI 32.49
    -DI 8.12
    Chandelier Exit (Long, 3 ATRs) 4.50
    Chandelier Exit (Short, 3 ATRs) 4.21
    Upper Bollinger Bands 6.03
    Lower Bollinger Band 2.79
    Percent B (%b) 0.88
    BandWidth 73.52
    MACD Line 0.64
    MACD Signal Line 0.56
    MACD Histogram 0.0737
    Fundamentals Value
    Market Cap 380.8 Million
    Num Shares 67.5 Million
    EPS 0.01
    Price-to-Earnings (P/E) Ratio 564.00
    Price-to-Sales 3.73
    Price-to-Book 2.49
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 6.22
    Resistance 3 (R3) 6.21 6.01 6.13
    Resistance 2 (R2) 6.01 5.86 6.01 6.09
    Resistance 1 (R1) 5.82 5.77 5.91 5.83 6.06
    Pivot Point 5.62 5.62 5.66 5.62 5.62
    Support 1 (S1) 5.43 5.47 5.53 5.45 5.22
    Support 2 (S2) 5.23 5.38 5.24 5.19
    Support 3 (S3) 5.05 5.23 5.16
    Support 4 (S4) 5.06